Press Releases

Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study

Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

Media Update: ECTRIMS: Sanofi showcases patient focus across multiple sclerosis

Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes

Media Update: ERS: new data across Sanofi’s immunology pipeline reinforce leadership in respiratory diseases

Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

Media Update: EADV: Sanofi builds on legacy in immunology with new data highlighting advances in treatment of chronic inflammatory skin diseases

Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease

Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.

Press release: Online availability of Sanofi’s half-year financial report for 2025

Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma

Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma

Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline

Press Release: Sanofi completes acquisition of Blueprint Medicines

Press Release: Sanofi announces extension of Blueprint tender offer

Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

Press release: Availability of the Q2 2025 Aide mémoire

Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy